3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Squamous Cell
2
Recurrence
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Lymphoid Interstitial Pneumonia
1
Lip Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma
1
Interventions
Cetuximab
14
Cisplatin
12
pembrolizumab
11
Paclitaxel
9
Gemcitabine
9
durvalumab
6
Nivolumab
6
Docetaxel
6
toripalimab
5
Carboplatin
5
Radiotherapy
4
Fluorouracil
4
Cyclophosphamide
4
fludarabine
3
Valproic Acid
3
Capecitabine
3
tremelimumab
2
spartalizumab
2
nimotuzumab
2
irinotecan sucrosofate
2
fludarabine phosphate
2
cemiplimab
2
anlotinib
2
Sunitinib
2
S 1 (combination)
2
Radiation
2
Oxaliplatin
2
NVP-BKM120
2
Methotrexate
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
ficlatuzumab
×
Head & Neck
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled